Gemigliptin tartrate 是一种选择性的，可逆的，竞争性的二肽基肽酶 4 (DPP-4) 抑制剂，对于人重组 DPP-4 的IC50=10.3 nM。Gemigliptin tartrate具有很强的抗糖基化活性，能够用于晚期糖基化终产物相关的糖尿病并发症的研究。

Gemigliptin tartrate is a highly selective, reversible and competitive inhibitor of dipeptidyl peptidase-4 (DPP-4). It has an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties.

Gemigliptin tartrate inhibits the formation of AGE-BSA with IC50 of 11.69 mM[1]. Gemigliptin tartrate suppresses the cross-linking of preformed AGE-BSA with rat tail tendon collagen with an IC50 of 1.39 mM[1]. Gemigliptin tartrate is a competitive DPP-4 inhibitor with a Ki of 7.25 nM[2].

Gemigliptin tartrate inhibits AGEs formation and AGE cross-links in vivo[1]. Gemigliptin tartrate dose-dependently inhibits plasma DPP-4 activity in rats, dogs, and monkeys[2].

1374639-74-3

C22H25F8N5O8

639.45

吉格列汀酒石酸盐;LC15-0444 tartrate

DMSO:90mg/ml(140.75mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years